Let's collaborate and create quality liposome encapsulated drugs together. Contact Us!
Development of liposomes
Development of liposome–mRNA formulations
Development of cationic LNP–mRNA formulations
Development of liposome–mRNA formulations as influenza vaccine
LNPs encapsulating small molecules (doxorubicin or amphotericin B) were approved by the FDA
LNPs encapsulating daunorubicin were approved by the FDA and the EMA
LNPs encapsulating verteporfin were approved by the FDA
LNPs encapsulating vincristine were approved by the FDA
Clinical trial of LNP–mRNA formulations for cancer immunotherapies (NCT02316457)
SyVento BioTech is founded with a commitment to develop lipid-based drug delivery systems. Leveraging their experience and expertise, the company focuses on creating innovative and effective lipid nanoparticle solutions for RNA-based medicine
• Clinical trial of LNP–mRNA formulations as influenza vaccines (NCT03076385)
• Clinical trial of LNP–mRNA formulationsfor protein replacement therapies (NCT03375047)
• First in-human test of personalized mRNA cancer vaccines
Onpattro (LNPs encapsulating siRNA), the first siRNA drug, was approved by the FDA and the EMA
• mRNA-1273 and BNT162b (LNP–mRNA
formulations) COVID-19 mRNA
vaccines obtained authorization from
regulatory agencies in multiple
countries
• Clinical trial of LNP formulations
delivering gene-editing components
for genetic disorders (NCT04601051)
SyVento and OncoArendi (currently Molecure) sign a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02, further solidifying SyVento's reputation in the field
SyVento BioTech opens its state-of-the-art R&D facility, expanding its research capabilities in lipid-based drug delivery systems and RNA-based medicine. This advanced research and production facility distinguishes the company as a standout in this part of the world, reflecting its commitment to innovation and excellence
Xucheng Hou, Tal Zaks, Robert Langer, Yizhou Dong. ” Lipid nanoparticles for mRNA delivery.” Nature Reviews Materials volume 6, (2021): pages1078–1094. https://doi.org/10.1038/s41578-021-00358-0
